SCHEMBL5456896

SCHEMBL5456896

CCCCc1ccc(S(=O)(=O)NC2CCCc3c2[nH]c2ccc(C)cc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RB1 P06400 1/20 0.56
GAA P10253 1/20 0.52
CASP6 P55212 1/20 0.52
PRMT5 O14744 2/20 0.52
SIRT1 Q96EB6 3/20 0.46
RECQL P46063 1/20 0.45
SIRT2 Q8IXJ6 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 6/20 0.44
TP53 P04637 4/20 0.44
LMNA P02545 3/20 0.43
CDKN1A P38936 1/20 0.42
THRB P10828 1/20 0.42
BRD3 Q15059 1/20 0.41
MLNR O43193 2/20 0.41
DRD2 P14416 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
DRD3 P35462 1/20 0.41
HTR6 P50406 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5445854 0.88 RB1 (0.63) RB1GAACASP6PRMT5SIRT1
SCHEMBL5458951 0.84 RB1 (0.59) RB1GAACASP6PRMT5SIRT1
SCHEMBL5455553 0.84 RB1 (0.59) RB1GAACASP6PRMT5SIRT1
SCHEMBL5449898 0.82 RB1 (0.56) RB1GAACASP6PRMT5SIRT1
SCHEMBL4025627 0.81 RB1 (0.59) RB1GAACASP6PRMT5SIRT1
SCHEMBL13772090 0.81 RB1 (0.59) RB1GAACASP6PRMT5SIRT1
SCHEMBL5461124 0.80 GAA (0.60) RB1GAACASP6PRMT5SIRT1
SCHEMBL14361123 0.80 RB1 (0.56) RB1GAACASP6PRMT5SIRT1
SCHEMBL5455558 0.78 RB1 (0.53) RB1GAACASP6PRMT5SIRT1
SCHEMBL16433500 0.77 GAA (0.77) GAACASP6PRMT5SIRT1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276009-A1 Compositions and Methods for Viral Inhibition MAVS, SARS1, ZC3HAV1 RB1 1821/4885GAA 1417/4885CASP6 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.